Analysts Set SAGE Therapeutics Inc (SAGE) Target Price at $175.75

SAGE Therapeutics Inc (NASDAQ:SAGE) has earned a consensus rating of “Buy” from the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $175.75.

A number of brokerages have issued reports on SAGE. BidaskClub cut shares of SAGE Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 13th. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, January 10th. Cowen restated a “buy” rating on shares of SAGE Therapeutics in a research report on Monday, December 11th. Stifel Nicolaus restated a “buy” rating and set a $198.00 price target on shares of SAGE Therapeutics in a research report on Friday, December 8th. Finally, SunTrust Banks boosted their price target on shares of SAGE Therapeutics to $178.00 and gave the company a “positive” rating in a research report on Friday, December 8th.

Shares of SAGE Therapeutics (SAGE) traded down $1.23 during mid-day trading on Tuesday, reaching $162.37. 467,420 shares of the company’s stock were exchanged, compared to its average volume of 697,206. SAGE Therapeutics has a 1-year low of $59.50 and a 1-year high of $195.97. The company has a market cap of $7,389.30, a PE ratio of -23.63 and a beta of 2.98.

In related news, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $157.45, for a total value of $33,103,390.15. Following the completion of the transaction, the chief executive officer now directly owns 211,473 shares in the company, valued at $33,296,423.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the transaction, the insider now owns 152,759 shares of the company’s stock, valued at $24,354,367.37. The disclosure for this sale can be found here. Insiders sold 314,247 shares of company stock valued at $50,465,110 over the last quarter. 6.10% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in SAGE Therapeutics by 36.5% in the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after purchasing an additional 724,494 shares during the last quarter. BlackRock Inc. raised its stake in shares of SAGE Therapeutics by 16.4% during the fourth quarter. BlackRock Inc. now owns 3,444,171 shares of the biopharmaceutical company’s stock valued at $567,290,000 after acquiring an additional 486,135 shares during the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of SAGE Therapeutics during the fourth quarter valued at about $74,300,000. Farallon Capital Management LLC raised its stake in shares of SAGE Therapeutics by 64.3% during the fourth quarter. Farallon Capital Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $65,884,000 after acquiring an additional 156,500 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of SAGE Therapeutics by 258.0% during the third quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock valued at $9,318,000 after acquiring an additional 107,782 shares during the last quarter. Institutional investors own 95.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Set SAGE Therapeutics Inc (SAGE) Target Price at $175.75” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/18/analysts-set-sage-therapeutics-inc-sage-target-price-at-175-75.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply